Biohaven Pharmaceutical Holding Company Ltd.

NYSE BHVN

Biohaven Pharmaceutical Holding Company Ltd. Price to Earnings Ratio (P/E) on February 05, 2025: -4.92

Biohaven Pharmaceutical Holding Company Ltd. Price to Earnings Ratio (P/E) is -4.92 on February 05, 2025, a 51.29% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Biohaven Pharmaceutical Holding Company Ltd. 52-week high Price to Earnings Ratio (P/E) is -4.26 on July 03, 2024, which is 13.50% above the current Price to Earnings Ratio (P/E).
Biohaven Pharmaceutical Holding Company Ltd. 52-week low Price to Earnings Ratio (P/E) is -12.80 on March 13, 2024, which is -160.12% below the current Price to Earnings Ratio (P/E).
Biohaven Pharmaceutical Holding Company Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.60.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NYSE: BHVN

Biohaven Pharmaceutical Holding Company Ltd.

CEO	Dr. Vladimir Coric M.D.
IPO Date	Sept. 23, 2022
Location	United States
Headquarters	215 Church Street
Employees	239
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Mental Health

Description

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years